Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
NHS England tried to sabotage hepatitis C drugs release because it couldn't afford them, doctors claim

NHS England tried to sabotage the release of hepatitis C drugs because it couldn't afford them, it has been claimed. Under current procedures, drugs approved by Nice typically become widely available to NHS patients after a statutory period of 90 days. However, the BMJ claims: “In an apparent panic over high prices and affordability, NHS England deployed many delaying tactics to block timely access to the hepatitis C drugs.”

Published
28 July 2016
From
The Independent
'Screen-and-treat' scheme for hepatitis B may prevent deadly complications

Research into Africa's first 'screen-and-treat' programme for hepatitis B suggests the initiative may reduce deadly complications of the virus. The new findings, from researchers at a number of international institutions including Imperial College London and the Medical Research Council Unit The Gambia, also suggest the initiative is feasible and cost-effective.

Published
27 July 2016
From
Eurekalert Inf Dis
CHMP Grants Positive Opinion for Shorter Treatment Duration with AbbVie's VIEKIRAX® for Patients with Genotype 4 Chronic Hepatitis C with Compensated Cirrhosis (Child-Pugh A)

AbbVie announced today that the European Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has granted a positive opinion for the use of 12 weeks of VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) with ribavirin (RBV) in genotype 4 (GT4) chronic hepatitis C virus (HCV) infected adult patients with compensated cirrhosis (Child-Pugh A). VIEKIRAX with RBV is currently approved in the European Union for GT4 patients with compensated cirrhosis for 24 weeks.

Published
26 July 2016
From
AbbVie press release
Sofosbuvir/velpatasvir shows high cure rate in HIV/HCV co-infection study

The once-daily co-formulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus (HCV) genotypes in people with HIV/HCV co-infection and was safe and well

Published
21 July 2016
By
Liz Highleyman
WHO Updates Patent Status Info For New Hepatitis C Medicines

The World Health Organization has issued updated information on the patent status of hepatitis C medicines, including assessments of hurdles for affordable generic versions of latest drugs.

Published
21 July 2016
From
Intellectual Property Watch
'World has ignored hepatitis at its peril,' warns UN health agency ahead of World Day

With some 400 million people around the world infected with hepatitis B or C, the United Nations health agency today encouraged countries to boost testing and access to services and medicines for people in need.

Published
21 July 2016
From
UN News Centre
The Lancet: Mass imprisonment of drug users driving global epidemics of HIV, hepatitis, and tuberculosis

The War on Drugs, mass incarceration of drug users, and the failure to provide proven harm reduction and treatment strategies has led to high levels of HIV, tuberculosis, and hepatitis B and C infection among prisoners--far higher than in the general population. With an estimated 30 million people passing in and out of prisons every year, prisoners will be key to controlling HIV and tuberculosis epidemics worldwide, according to a major six-part Series on HIV and related infections in prisoners, published in The Lancet and being presented at the International AIDS Conference in Durban, South Africa.

Published
17 July 2016
From
EurekAlert
Fast Advance in Hepatitis C Care Prompts EMA to Revise Clinical Trial Guideline

EMA has proposed changes to its guideline on clinical trials of direct acting antiviral hepatitis C drugs. The revisions are intended to ensure the guideline reflects the dramatic changes that have happened in the hepatitis C sector since Gilead introduced its blockbuster Sovaldi (sofosbuvir).

Published
17 July 2016
From
Regulatory Affairs Professionals Society
Treatment Action Group: Pipeline Report 2016

Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Development.

Published
15 July 2016
From
Treatment Action Group
Complete clearance of hepatitis B is rare - especially in women and people of Asian descent

Researchers at several different US sites have found that less than one-third of 1% of patients infected with hepatitis B virus (HBV) get rid of the virus per year, and overall, only 1.2% of patients finally get rid of it.

Published
12 July 2016
From
Eurekalert Inf Dis

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close